Top Markets
Coin of the day
Gamida Cell Ltd. Gamida Cell Ltd.

Gamida Cell Ltd.

GMDA
株式のランク #35164
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated... Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
株価
$0.0327
最終同期: 2025-06-17
時価総額
$4.34M
変化(1日)
0.00%
変化(1年)
0.00%
IL
取引 Gamida Cell Ltd. (GMDA)

カテゴリー

Gamida Cell Ltd.(GMDA)の株式分割履歴
Gamida Cell Ltd.株(シンボル:GMDA)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 16, 2026に行われました。
Aug 16, 2026より前に購入されたGMDA株は、現在0GMDA株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE